Comparative Pharmacology
Head-to-head clinical analysis: ANCEF IN DEXTROSE 5 IN PLASTIC CONTAINER versus CEFUROXIME SODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANCEF IN DEXTROSE 5 IN PLASTIC CONTAINER versus CEFUROXIME SODIUM.
ANCEF IN DEXTROSE 5% IN PLASTIC CONTAINER vs CEFUROXIME SODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cefazolin is a first-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation and disrupting peptidoglycan cross-linking. This leads to cell lysis and death, primarily in actively dividing bacteria.
Cefuroxime sodium is a second-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), disrupting peptidoglycan cross-linking.
For uncomplicated infections: 1-2 g IV every 8 hours. For severe infections: up to 2 g IV every 4 hours. Administered as an IV infusion over 30-60 minutes.
750 mg to 1.5 g IV or IM every 8 hours; maximum 6 g per day.
None Documented
None Documented
1.8 hours (normal renal function); prolonged to 10-30 hours in severe renal impairment (CrCl <10 mL/min)
Terminal elimination half-life: 1.2 hours (range 1-2 hours) in patients with normal renal function; prolonged to 15-22 hours in end-stage renal disease (CrCl <10 mL/min); dosing adjustment required for CrCl <30 mL/min
Renal: >80% unchanged via glomerular filtration and tubular secretion; biliary/fecal: <1%
Renal (95% unchanged via glomerular filtration and tubular secretion); biliary/fecal (minimal, <5%)
Category C
Category A/B
Cephalosporin Antibiotic
Cephalosporin Antibiotic